Does Semaglutide Cause Postmenopausal Bleeding?
Based on FDA labeling and available evidence, postmenopausal uterine bleeding is not a recognized adverse effect of semaglutide (Ozempic, Rybelsus). The official FDA prescribing information does not list postmenopausal bleeding or any uterine bleeding as an adverse reaction 1.
Evidence Analysis
FDA Drug Labeling (Highest Priority)
The comprehensive FDA warnings and adverse reactions sections for semaglutide products detail multiple side effects including:
- Gastrointestinal reactions (nausea, vomiting, diarrhea - most common)
- Diabetic retinopathy complications
- Acute kidney injury
- Gallbladder disease
- Hypoglycemia (when combined with insulin/secretagogues)
- Hypersensitivity reactions
Notably absent from this extensive list is any mention of vaginal bleeding, uterine bleeding, or menstrual irregularities 1.
Pharmacokinetic Data
A dedicated drug interaction study specifically examined oral semaglutide's effects on hormonal contraceptives (ethinylestradiol and levonorgestrel) in postmenopausal women. The study found no clinically significant interaction - semaglutide did not alter the pharmacokinetics of these hormones (AUC ratios 1.06 for both compounds, within the 0.80-1.25 no-effect interval) 2. This suggests semaglutide does not interfere with hormonal pathways that could trigger bleeding.
Case Report Consideration
One case report describes vaginal bleeding with dulaglutide (a different GLP-1 receptor agonist, not semaglutide) in a 44-year-old perimenopausal woman 3. However, this involves:
- A different medication in the same class
- A perimenopausal (not postmenopausal) patient
- An isolated case report (lowest quality evidence)
- No established mechanism
This single case with a different drug does not establish causation for semaglutide.
Clinical Approach
If Postmenopausal Bleeding Occurs on Semaglutide:
Do not attribute the bleeding to semaglutide - investigate for standard causes of postmenopausal bleeding
Evaluate immediately for:
- Endometrial pathology (cancer, hyperplasia, polyps)
- Atrophic vaginitis/endometritis
- Cervical lesions
- Coagulation disorders
- Other medications (hormone therapy, anticoagulants, tamoxifen)
Initial diagnostic approach 4:
- Transvaginal ultrasound: if endometrial thickness ≤4 mm, expectant management acceptable
- OR endometrial sampling (biopsy)
- If endometrial thickness >4 mm: proceed to endometrial sampling
Continue semaglutide unless another cause is identified that requires its discontinuation
Important Caveats
- The weight loss induced by semaglutide may affect hormone levels in obese postmenopausal women (increased estrogen from adipose tissue conversion), but this is an indirect effect of weight loss, not a direct drug effect
- One study showed postmenopausal women on hormone therapy had better weight loss response to semaglutide 5, but this addresses efficacy, not bleeding risk
- GLP-1 receptor agonists as a class have not been associated with uterine bleeding in major cardiovascular outcomes trials 6, 7
Bottom line: Postmenopausal bleeding in a patient taking semaglutide requires standard gynecologic evaluation for malignancy and other pathology - it should not be dismissed as a drug side effect.